Onxeo announces evolution in the Board of Directors — Onxeo offentliggør ændring i bestyrelsen

  • Mr. Patrick Langlois is planning to step down from the chairmanship in early 2016 for personal reasons
  • Mr. Joseph Zakrzewski is joining the Board and is expected to be appointed Non-Executive Chairman in 2016

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative biopharmaceutical company specializing in the development of orphan oncology drugs, today announced that Mr. Joseph Zakrzewski is joining the Board of Directors as a Permanent Attendee with the view of being appointed Board Member and Non-Executive Chairman early 2016. Mr. Patrick Langlois, currently Non-Executive Chairman of the Board, has announced that he will step down from his chairmanship and board position for personal reasons and will pass his responsibility to Mr. Zakrzewski after the board meeting scheduled for the end of January 2016.

When Mr. Joseph Zakrzewski is appointed as chairman, Mrs. Danièle Guyot-Caparros, board member and Chairman of the Audit Committee, will be appointed Senior Independent Director in charge of good governance practices, especially in the French environment.

Mr. Joseph Zakrzewski has more than 25 years of experience in the global healthcare industry with a focus in the United States, where he has successfully handled leadership positions in public and private companies as well as venture capital. Throughout his career, he has developed an extensive range of expertise, heading Global Corporate Business Development for Eli Lilly prior to being appointed to executive positions at biotechnology companies (Reliant Pharmaceuticals, Xcellerex, and Amarin) where he acquired a broad knowledge of the US biotechnology environment, innovation management, and healthcare-specialized financing. Mr. Zakrzewski currently holds board member positions with a number of US and European healthcare companies.

 “We are delighted to welcome Joe to Onxeo. His experience in corporate development, his knowledge of the US healthcare environment and the financial community are impressive and I am pleased to hand over my responsibilities to him. We are convinced that Joe will bring a sound value to the Board of Directors in supporting the management team as it continues to drive the company forward. Over the coming months we are planning on a smooth transition in early 2016” comments Patrick Langlois, Chairman of the Board of Onxeo. “I have been privileged to witness and contribute to Onxeo’s new focus on high potential orphan oncology products. I am very proud of what we have achieved, together with the Board of Directors and the management team that I would like to thank them both for their trust and commitment”.    

Mr. Joseph Zakrzewski, Permanent Attendee and future Chairman of the Board of Directors of Onxeo, added: “Onxeo is a very promising company with a clear position in an attractive market, a large and well-advanced pipeline and a strong management team. I am delighted to join Onxeo’s board, a group of highly experienced professionals and I am impressed with the level of commitment and professionalism shown within the company. I truly believe that this company has everything it needs to build a great future and I am very excited to have the opportunity to be part of this entrepreneurial adventure that I will support in all  possible ways”.

Biography:

Joseph Zakrzewski has more than 25 years of experience in the healthcare industry. His career started with Eli Lilly & Company in the USA: He joined as process engineer with responsibility for biologics development & manufacturing (1988-1991), became Senior Financial Analyst (1991-1993) and Head of Manufacturing and Development (1993-1995), then Manager and Director of Corporate Business Development (1995-2003), before being appointed VP Global Corporate Business Development (2003-2005). He was Chief Operating Officer of Reliant Pharmaceuticals (2005-2007), and then joined the biotechnology company Xcellerex as CEO (2007-2010). From 2010 to 2013, he was Chairman and CEO of Amarin Corporation (Ireland), where he remains a director. He has also been a venture partner at Orbimed Advisors, one of the leading VC funds dedicated to the healthcare industry (2010-2011).

Joseph Zakrzewski is a board member with several biotechnology companies in Europe and in the USA, public and private, including Insulet Corporation, Amarin Corporation, Thrasos Therapeutics, Acceleron Pharma, Gliacure Inc., and SiteOne Therapeutics.

A US citizen, Joseph Zakrzewski received a BS in Chemical Engineering and an MS in Biochemical Engineering from Drexel University. He has an MBA in Finance from the University of Indiana.

151006EN – Appointment Joseph Zakrzewski

  • Patrick Langlois planlægger at fratræde som bestyrelsesformand i starten af 2016 af personlige årsager
  • Joseph Zakrzewski indtræder i bestyrelsen og ventes at blive udnævnt til ekstern formand i 2016

Paris (Frankrig), København (Danmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), et innovativt biofarmaceutisk selskab med speciale i udvikling af lægemidler til behandling af sjældne kræftsygdomme, har i dag meddelt, at Joseph Zakrzewski indtræder i bestyrelsen som permanent observatør med henblik på at blive valgt som bestyrelsesmedlem og ekstern bestyrelsesformand, forventeligt i starten af 2016. Patrick Langlois, den nuværende eksterne bestyrelsesformand, har meddelt, at han fratræder som formand og bestyrelsesmedlem af personlige årsager, og at han vil overdrage sine forpligtelser til Joseph Zakrzewski efter det bestyrelsesmøde, der planlægges afholdt i slutningen af januar 2016.

Når Joseph Zakrzewski tiltræder som bestyrelsesformand, vil Danièle Guyot-Caparros, som er bestyrelsesmedlem og formand for revisionskomitéen, blive udnævnt til Senior Independent Director med ansvar for god selskabsledelse, især med hensyn til franske forhold.

Joseph Zakrzewski har over 25 års erfaring fra den globale lægemiddelbranche med fokus på USA, hvor han har bestredet lederstillinger i offentlige og private selskaber samt inden for venturekapital. I løbet af sin karriere har han oparbejdet ekspertise på flere områder, først som leder af den globale forretningsudvikling hos Eli-Lilly og derefter i ledende stillinger i biotekselskaber (Reliant Pharmaceuticals, Xcellerex og Amarin), hvor han opbyggede et indgående kendskab til den amerikanske biotekverden, innovationsledelse og finansiering inden for sundhedssektoren. Joseph Zakrzewski er i dag bestyrelsesmedlem i en række amerikanske og europæiske lægemiddelvirksomheder.

“Vi er glade for at byde Joseph velkommen til Onxeo. Hans erfaring med selskabsudvikling, hans indsigt i den amerikanske lægemiddelindustri og finansverden er ganske imponerende, og det er mig en glæde at overlade formandsposten til ham. Vi er overbeviste om, at Joseph vil tilføre stor værdi til bestyrelsen og støtte direktionen i at opnå den vækst, som Onxeo fortjener. I de kommende måneder vil vi planlægge og arbejde hen imod en smidig overgang i starten af 2016,” udtaler Onxeos bestyrelsesformand Patrick Langlois. “Jeg har nydt at være vidne til og bidrage til Onxeos nye fokus på attraktive lægemidler til behandling af sjældne kræftsygdomme. Jeg er yderst stolt af de resultater, vi i bestyrelsen har opnået sammen med den daglige ledelse, og jeg vil gerne takke alle for deres tillid og engagement”.

Joseph Zakrzewski, permanent observatør i bestyrelsen og kommende formand for bestyrelsen i Onxeo, tilføjer: “Onxeo er et yderst lovende selskab med en tydelig position på et attraktivt marked, en stor og fremskreden pipeline og en stærk ledelse. Jeg er glad for at indtræde i Onxeos bestyrelse, hvis medlemmer er yderst erfarne, og jeg er imponeret over det store engagement og den professionelle tilgang i selskabet. Jeg er overbevist om, at Onxeo har det, der skal til for at bygge en stor fremtid, og jeg glæder mig til at blive en del af dette spændende eventyr, som jeg vil bidrage til på alle måder”.

Biografi:

Joseph Zakrzewski har mere end 25 års erfaring fra lægemiddelindustrien. Han startede sin karriere hos Eli Lilly & Company i USA, hvor han startede som procesingeniør med ansvar for biologisk udvikling og fremstilling (1988-1991); han blev derefter Senior Financial Analyst (1991-1993) og leder af produktion og udvikling (1993-1995), derefter Manager og Director of Corporate Business Development (1995-2003), og endelig blev han udnævnt til VP Global Corporate Business Development (2003-2005). Han var Chief Operating Officer hos Reliant Pharmaceuticals (2005-2007) og tiltrådte derefter som administrerende direktør for Xcellerex (2007-2010). Fra 2010 til 2013 var han bestyrelsesformand og administrerende direktør for Amarin Corporation (Irland), hvor han fortsat er bestyrelsesmedlem. Han har også været venturepartner hos Orbimed Advisors, som er en af de førende venturekapitalfonde med fokus på lægemiddelindustrien (2010-2011).

Joseph Zakrzewski er bestyrelsesmedlem i en række biotekselskaber i Europa og USA, både offentlige og private. Disse omfatter Insulet Corporation, Amarin Corporation, Thrasos Therapeutics, Acceleron Pharma, Gliacure Inc og SiteOne Therapeutics.

Joseph Zakrzewski er amerikansk statsborger og har en bachelorgrad i Chemical Engineering og en masters-grad i Biochemical Engineering fra Drexel University i USA. Han har en MBA i finansiering fra University of Indiana, USA.

151006DK – Appointment Joseph Zakrzewski